Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Lipocine Inc.

35 indications, side-by-side phase, drug & LoA

$2.26

+0.09 (+4.09%)

C 52Pipeline Score Undervalued Pharma · Clinical
Market Cap
18.63 M
EPS
-1.96
P/E Ratio
-
Value Trade
132.19 K
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    119.40 K

  • R&D Expenses

    2.76 M

  • Operating CF

    -2.26 M

  • Total Assets

    25.36 M

  • Total Liabilities

    2.53 M

  • Equity

    22.83 M

  • D/E Ratio

    12,345

-1.31 %
Week
-3.42 %
1 Month
-75.59 %
3 Month
-28.48 %
6 Month
-90.51 %
5 Year
-99.34 %
All Time
Cash Data
Healthy

  • Cash Position

    24.73 M

  • Monthly Burn

    752.00 K

  • Runway

    31.8 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 7, 2026
Overview
Volume
203.73 K
52 Week Range
1.81 - 12.37
% held by Insiders
4.53 %
% held by Institutions
37.83 %
Enterprise Value
-6.10 M
Total Shares
5.55 M
Short %
1.74 %
Float Shares
5.19 M
Company Description
HQ: 675 ARAPEEN DRIVE, SUITE 202, ...
Employees:14
https://www.lipocine.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 3 data readout example
LPCN 1154 Postpartum Depression (PPD)
Phase 3
—
Small Molecules
Psychiatric Disorders
LPCN 1154 Postpartum Depression (PPD)
Phase 3
—
Small Molecules
Psychiatric Disorders
LPCN 1154 Postpartum Depression (PPD)
Phase 3
—
Small Molecules
Psychiatric Disorders
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C52
Pipeline Score
$145M
Pipeline Value
Undervalued
Valuation Signal
6
Drugs Scored
7.8x
rNPV / MCap
Top 75%
Micro Cap
(rank 227 of 905)
Percentile Rank
Lipocine Inc. carries a moderate pipeline score (52/100), with $2.9B risk-adjusted pipeline value, led by testosterone undecanoate, LPCN 1021 in Male Hypogonadism (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
testosterone undecanoate, LPCN 1021
Small molecule		Male HypogonadismPhase 3NCT0208130060% $898M COMPLETED 315 - -May 1, 2015 -Oct 23, 2017
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
LPCN 2401
Obesity,Metabolic dysfunction associated steatohepatitis
Phase 2
2025-11-04
LPCN 2401
Obesity,Metabolic dysfunction associated steatohepatitis
Phase 2
2025-11-04
LPCN 2401
Obesity,Metabolic dysfunction associated steatohepatitis
Phase 2
2025-11-04
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in LPCN
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
LPCN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LPCN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LPCN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
LPCN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
LPCN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Lipocine Inc. (LPCN) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How LPCN ranks across every disease it competes in
No competitive intelligence available for LPCN.